---
title: "MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295434879.md"
description: "MoonLake Immunotherapeutics announced positive Phase 3 IZAR-1 trial results for sonelokimab in biologic-naïve psoriatic arthritis patients, meeting all primary and secondary endpoints. Despite clinical success, the stock fell over 6%. The company holds $537 million in cash, extending its runway through mid-2028. Enrollment for the companion IZAR-2 trial is expected to complete by Q3 2026."
datetime: "2026-08-10T17:21:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295434879.md)
  - [en](https://longbridge.com/en/news/295434879.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295434879.md)
generator: "portal-rs"
---

# MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study

**MoonLake Immunotherapeutics** (NASDAQ:MLTX) announced positive Week 16 topline results from its Phase 3 IZAR-1 trial evaluating sonelokimab in biologic-naïve adults with active psoriatic arthritis.

Following the announcement, the stock fell over 6%.

## Phase 3 IZAR-1 Trial Key Results

The Phase 3 trial successfully met all primary and secondary clinical endpoints at Week 16 for the 60 mg sonelokimab treatment arm with induction.

A total of 42.1% of biologic-naïve participants achieved the primary endpoint of an American College of Rheumatology 50 response.

Secondary clinical endpoints demonstrated broad efficacy across musculoskeletal and physical outcomes, with 66.5% of patients achieving an ACR20 response and 41.2% attaining Minimal Disease Activity.

## Multidomain Efficacy And Safety

For patients exhibiting concomitant skin involvement, 61% reached a Psoriasis Area and Severity Index 90 response at Week 16.

Patients also showed clinically meaningful improvements in quality of life, recording a mean baseline change of -0.427 in HAQ-DI and a 6.54 score in the SF-36 Physical Component Summary.

Blinded safety data remained consistent with previous clinical studies, showing no new safety signals and a low dropout rate.

 **Read Also: FDA Aligns With MoonLake On Lead Drug Submission Plans, Stock Soars** 

## Program Timeline And Financial Status

The IZAR-1 trial will remain blinded and run through Week 52, with a comprehensive readout expected in the first half of 2027. 

Meanwhile, enrollment for the companion IZAR-2 trial in TNF-refractory patients is slated for completion in the third quarter of 2026. 

These trial outcomes set the stage for sonelokimab to target another multi-billion dollar indication after hidradenitis suppurativa.

From a financial perspective, the biotechnology company reported holding $537.0 million in cash, cash equivalents, and short-term marketable debt securities as of June 30, 2026.

The company anticipates that this capital reserve will be sufficient to support its operational expenses and capital expenditure requirements into mid-2028.

**MLTX Stock Price Activity**: MoonLake shares were down 6.30% at $17.11 at the time of publication on Monday,  
according to Benzinga Pro data.

*Image via Shutterstock*

 **Read Also: Microsoft Stock Rises 2%: Upcoming Maia 300 Chip Launch Targets Reduced Nvidia Reliance**

### Related Stocks

- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)
- [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md)
- [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md)
- [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md)

## Related News & Research

- [MoonLake's psoriatic arthritis drug meets key goals in late-stage trial](https://longbridge.com/en/news/295404482.md)
- [Dimensional Fund Advisors LP Has $490,000 Position in MoonLake Immunotherapeutics $MLTX](https://longbridge.com/en/news/296016200.md)
- [GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy](https://longbridge.com/en/news/296748151.md)
- [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | TAK Stock News](https://longbridge.com/en/news/296745786.md)
- [Is Royalty Pharma (RPRX) Undervalued On Its $100 Million Zealand Pharma Royalty Deal?](https://longbridge.com/en/news/296647266.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**